SSA
DMAC icon

Schonfeld Strategic Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,483
Closed -$62.5K – 2146
2025
Q1 		$62.5K Sell
16,483
-9,614
-37% -$55K ﹤0.01% 2061
2024
Q4 		$142K Buy
+26,097
New +$123K ﹤0.01% 1812
2021
Q1 		– Sell
-66,250
Closed -$671K – 1865
2020
Q4 		$671K Buy
+66,250
New +$362K 0.01% 941

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Schonfeld Strategic Advisors's DMAC Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of DiaMedica Therapeutics (DMAC) in Q2 2025, closing a stake of 16,483 shares — an estimated $62.5K sold.

Schonfeld Strategic Advisors first reported a position in DMAC in Q4 2020 and held it in 3 quarters. The position peaked at $671K in Q4 2020. 58 funds tracked by Wall St. Rank hold DMAC as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining DiaMedica Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 16,483 DiaMedica Therapeutics shares in Q2 2025, an estimated $62.5K.
  • Schonfeld Strategic Advisors first reported a position in DiaMedica Therapeutics in Q4 2020 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's DiaMedica Therapeutics position peaked at $671K in Q4 2020.
  • 58 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.